Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
NPD Measurements in PSC Patients
This study is not yet open for participant recruitment.
Verified by Hadassah Medical Organization, October 2007
Sponsored by: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00476814
  Purpose

Primary Sclerosing Cholangitis (PSC) is a chronic disorder of the liver causing jaundice and liver damage. When Cystic Fibrosis affects the liver, the damaged liver looks like the liver in PSC. This study is designed to answer the question whether isolated PSC may be a form of CF only in the liver


Condition
Primary Sclerosing Cholangitis

Genetics Home Reference related topics: cystic fibrosis
MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Cystic fibrosis transmembrane conductance regulator
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Cystic Fibrosis Transmembrane Conductance Regulator Function as Measured by Nasal Potential Difference Measurements in Patients With Primary Sclerosing Cholangitis

Further study details as provided by Hadassah Medical Organization:

Detailed Description:

Cystic Fibrosis (CF) is a progressive autosomal recessive disorder caused by defects in the cystic fibrosis transmembrane conductance regulator gene (CFTR). CFTR mutations cause loss or impairment of CFTR-mediated ion transport across epithelial cell membranes. CF affects many organs including the respiratory tract, pancreas, intestine, liver and the male reproductive tract. Liver disease occurs less frequently than pulmonary disease. CFTR is expressed in the bile duct epithelial cells and is responsible for the hydration of biliary secretions.

CF was until recently, thought to be a multi-organ disease. However, there are now recognized non-classical presentations of CF involving a few organs only and now there is well established data on single -organ involvement including Congenital Absence of the Vas Deferens and recurrent pancreatitis.

CF and PSC have several features in common. They both affect intrahepatic bile ducts by inspisated biliary secretions, chronic inflammation and fibrosis. Is PSC the "single-organ presentation" of CF? Patients with PSC will undergo testing of the CF protein channel by nasal potential testing. This test is performed by insering a thin plastic tube 2 to 3 cms into the nostril and chloride transport can be measured. This test may shows that the patient has an abnormality in the CF protein channel.

  Eligibility

Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Age > 10 years
  • Patients diagnosed as Non-IBD PSC
  • Patients diagnosed as IBD PSC

Exclusion Criteria:

  • Age < 10 years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00476814

Contacts
Contact: Michael Wilschanski, Dr. 972-2-5844922 michaelwil@hadassah.org.il

Locations
Israel
Hadassah Medical Organization
Jerusalem, Israel, 91240
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Michael Wilschanski, Dr Hadassah Medical Organization
  More Information

Study ID Numbers: will002-HMO-CTIL
Study First Received: May 21, 2007
Last Updated: October 30, 2007
ClinicalTrials.gov Identifier: NCT00476814  
Health Authority: Israel: Ministry of Health

Keywords provided by Hadassah Medical Organization:
cystic fibrosis,
nasal potential difference,
primary sclerosing cholangitis

Study placed in the following topic categories:
Primary sclerosing cholangitis
Cholangitis, Sclerosing
Fibrosis
Cholangitis
Digestive System Diseases
Cystic Fibrosis
Respiratory Tract Diseases
Genetic Diseases, Inborn
Bile Duct Diseases
Biliary Tract Diseases
Lung Diseases
Pancreatic Diseases
Infant, Newborn, Diseases
Cystic fibrosis

ClinicalTrials.gov processed this record on January 16, 2009